These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy]. Shao Q, Song J, Zhou ZJ, Du LD. Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378 [Abstract] [Full Text] [Related]
34. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW. J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682 [Abstract] [Full Text] [Related]
35. [Usefulness of PSA-complex in the diagnosis of prostatic carcinoma]. Martín Vega A, Moreno Sierra J, Ortega Heredia MD, López García-Asenjo JA, Fernández Pérez C, Redondo González E, Bocardo Fajardo G, Valor Perea R, Silmi Moyano A, Blanco Jiménez LE, Resel Estévez L. Arch Esp Urol; 2000 Nov; 53(9):776-82. PubMed ID: 11196384 [Abstract] [Full Text] [Related]
36. Complexed prostate specific antigen: better test in the diagnosis of prostate cancer for the clinically relevant 2.5-4 ng/ml total PSA range. Mutlu N, Türkeri LN, Yencilek F, Demir A, Emerk K. Can J Urol; 2009 Apr; 16(2):4558-67. PubMed ID: 19364428 [Abstract] [Full Text] [Related]
37. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H. J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872 [Abstract] [Full Text] [Related]
38. The use of complexed PSA for the early detection of prostate cancer. Fischer K, Loertzer H, Fornara P. Anticancer Res; 2005 Jan; 25(3A):1591-6. PubMed ID: 16033065 [Abstract] [Full Text] [Related]
39. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience. Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R. J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232 [Abstract] [Full Text] [Related]